Abatacept News and Research

RSS
Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFa therapy.
NIH launches adaptive Phase 3 clinical trial to test immune modulator drugs in COVID-19 patients

NIH launches adaptive Phase 3 clinical trial to test immune modulator drugs in COVID-19 patients

New biomarker may help identify patients at risk for graft-versus-host disease after stem cell transplants

New biomarker may help identify patients at risk for graft-versus-host disease after stem cell transplants

New biomarkers may identify Type 1 diabetes patients who could benefit from immunotherapy

New biomarkers may identify Type 1 diabetes patients who could benefit from immunotherapy

A major step toward preventing GvHD in patients receiving bone marrow transplants

A major step toward preventing GvHD in patients receiving bone marrow transplants

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis – new treatments wanted

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

New immunosuppressive regimens may improve outcomes for kidney transplant patients

New immunosuppressive regimens may improve outcomes for kidney transplant patients

Drug improves disease-free, overall survival after hematopoietic stem cell transplants

Drug improves disease-free, overall survival after hematopoietic stem cell transplants

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Biologic drugs may help prevent progressive bone loss in patients with RA

Biologic drugs may help prevent progressive bone loss in patients with RA

Anti-CPP presence in bloodstream of RA patients correlates with drug response

Anti-CPP presence in bloodstream of RA patients correlates with drug response

Treatment with rheumatoid arthritis drug saved transplanted kidney and achieved remission

Treatment with rheumatoid arthritis drug saved transplanted kidney and achieved remission

ACR journals publish guide that provides new treatments for children with systemic JIA

ACR journals publish guide that provides new treatments for children with systemic JIA

Vanderbilt examines ability of drug abatacept to prevent type 1 diabetes

Vanderbilt examines ability of drug abatacept to prevent type 1 diabetes

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Updated EULAR recommendations for management of rheumatoid arthritis

Updated EULAR recommendations for management of rheumatoid arthritis

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

University of Cincinnati to lead Belatacept Early Steroid withdrawal Trial

University of Cincinnati to lead Belatacept Early Steroid withdrawal Trial

'No malignancy risk' with biologic response modifiers

'No malignancy risk' with biologic response modifiers